(Damistimagene matitucel + enistimagene setitucel) is under clinical development by Chinook Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect (Damistimagene matitucel + enistimagene setitucel)’s likelihood of approval (LoA) and phase transition for Metastatic Adenocarcinoma of The Pancreas took place on 19 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their (Damistimagene matitucel + enistimagene setitucel) Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

(Damistimagene matitucel + enistimagene setitucel) overview

Damistimagene matitucel in a fixed-dose combination with enistimagene setitucel (GVAX pancreatic cancer vaccine) is under development for the treatment of metastatic pancreatic adenocarcinoma. It is administered intradermally. The vaccine candidate comprises of two allogeneic irradiated pancreatic tumor cell lines, Panc 10.05 and Panc 6.03, which are genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF). The vaccine candidate is developed based on GVAX platform technology.

Chinook Therapeutics overview

Chinook Therapeutics, Inc (Chinook)., formerly Aduro BioTech Inc is a clinical-stage immunotherapy company that discovers, develops and commercializes therapies for the treatment of cancer. The company develops product candidates using proprietary technology platforms such as live, attenuated, double-deleted listeria, sting pathway activators; and B-select monoclonal antibodies to create immunotherapies for the treatment of cancers, infectious and autoimmune diseases. Its products are under development and are intended for the treatment of variety of cancers, including metastatic colorectal, multiple myeloma cancers, as well as other solid tumors and lymphomas. The company collaborates with various pharmaceutical companies to expand its products, and technology platforms. It has an operational presence in The Netherlands. Chinook is headquartered in Berkeley, California, the US.

Quick View (Damistimagene matitucel + enistimagene setitucel) LOA Data

Report Segments
  • Innovator
Drug Name
  • (Damistimagene matitucel + enistimagene setitucel)
Administration Pathway
  • Intradermal
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.